Literature DB >> 16731948

Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity.

Robyn L Stanfield1, Miroslaw K Gorny, Susan Zolla-Pazner, Ian A Wilson.   

Abstract

Human monoclonal antibody 2219 is a neutralizing antibody isolated from a human immunodeficiency virus type 1-infected individual. 2219 was originally selected for binding to a V3 fusion protein and can neutralize primary isolates from subtypes B, A, and F. Thus, 2219 represents a cross-reactive, human anti-V3 antibody. Fab 2219 binds to one face of the variable V3 beta-hairpin, primarily contacting conserved residues on the N-terminal beta-strand of V3, leaving the V3 crown or tip largely accessible. Three V3/2219 complexes reveal the antibody-bound conformations for both the N- and C-terminal regions that flank the V3 crown and illustrate how twisting of the V3 loop alters the relative dispositions and pairing of the amino acids in the adjacent V3 beta-strands and how the antibody can accommodate V3 loops with different sequences.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731948      PMCID: PMC1472588          DOI: 10.1128/JVI.00205-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  79 in total

1.  Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs.

Authors:  R Stanfield; E Cabezas; A Satterthwait; E Stura; A Profy; I Wilson
Journal:  Structure       Date:  1999-02-15       Impact factor: 5.006

2.  Solution conformation of a peptide corresponding to the principal neutralizing determinant of HIV-1IIIB: a two-dimensional NMR study.

Authors:  A Zvi; R Hiller; J Anglister
Journal:  Biochemistry       Date:  1992-08-04       Impact factor: 3.162

3.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

Authors:  C D Rizzuto; R Wyatt; N Hernández-Ramos; Y Sun; P D Kwong; W A Hendrickson; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

4.  Synthesis, characterization and conformational analysis of gp 120-derived synthetic peptides that specifically enhance HIV-1 infectivity.

Authors:  M Dettin; R Roncon; M Simonetti; S Tormene; L Falcigno; L Paolillo; C Di Bello
Journal:  J Pept Sci       Date:  1997 Jan-Feb       Impact factor: 1.905

5.  Structural families in loops of homologous proteins: automatic classification, modelling and application to antibodies.

Authors:  A C Martin; J M Thornton
Journal:  J Mol Biol       Date:  1996-11-15       Impact factor: 5.469

6.  NMR study of the peptide present in the principal neutralizing determinant (PND) of HIV-1 envelope glycoprotein gp120.

Authors:  A V Sarma; T V Raju; A C Kunwar
Journal:  J Biochem Biophys Methods       Date:  1997-03-27

7.  The complete Consensus V3 loop peptide of the envelope protein gp120 of HIV-1 shows pronounced helical character in solution.

Authors:  W F Vranken; M Budesinsky; F Fant; K Boulez; F A Borremans
Journal:  FEBS Lett       Date:  1995-10-23       Impact factor: 4.124

Review 8.  HIV-1 envelope determinants for cell tropism and chemokine receptor use.

Authors:  T L Hoffman; R W Doms
Journal:  Mol Membr Biol       Date:  1999 Jan-Mar       Impact factor: 2.857

9.  Secondary structural elements as a basis for antibody recognition in the immunodominant region of human immunodeficiency viruses 1 and 2.

Authors:  R L Markert; H Ruppach; S Gehring; U Dietrich; D F Mierke; M Köck; H Rübsamen-Waigmann; C Griesinger
Journal:  Eur J Biochem       Date:  1996-04-01

10.  Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF.

Authors:  H M Vu; R de Lorimier; M A Moody; B F Haynes; L D Spicer
Journal:  Biochemistry       Date:  1996-04-23       Impact factor: 3.162

View more
  71 in total

1.  Conserved structural elements in the V3 crown of HIV-1 gp120.

Authors:  Xunqing Jiang; Valicia Burke; Maxim Totrov; Constance Williams; Timothy Cardozo; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Nat Struct Mol Biol       Date:  2010-07-11       Impact factor: 15.369

2.  Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.

Authors:  Christian H Bell; Ralph Pantophlet; André Schiefner; Lisa A Cavacini; Robyn L Stanfield; Dennis R Burton; Ian A Wilson
Journal:  J Mol Biol       Date:  2007-11-13       Impact factor: 5.469

3.  Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

Authors:  Ralph Pantophlet; Rowena O Aguilar-Sino; Terri Wrin; Lisa A Cavacini; Dennis R Burton
Journal:  Virology       Date:  2007-04-06       Impact factor: 3.616

4.  Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.

Authors:  Milloni B Patel; Noah G Hoffman; Ronald Swanstrom
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

5.  Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain.

Authors:  Jeffrey E Lee; Ana Kuehne; Dafna M Abelson; Marnie L Fusco; Mary Kate Hart; Erica Ollmann Saphire
Journal:  J Mol Biol       Date:  2007-10-16       Impact factor: 5.469

6.  Individuals with HIV-1 Subtype C Infection and Cryptococcal Meningitis Exhibit Viral Genetic Intermixing of HIV-1 Between Plasma and Cerebrospinal Fluid and a High Prevalence of CXCR4-Using Variants.

Authors:  Katlego Sojane; Richard T Kangethe; Christina C Chang; Mahomed-Yunus S Moosa; Sharon R Lewin; Martyn A French; Thumbi Ndung'u
Journal:  AIDS Res Hum Retroviruses       Date:  2018-05-23       Impact factor: 2.205

7.  Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set.

Authors:  Amandeep K Dhillon; Robyn L Stanfield; Miroslaw K Gorny; Constance Williams; Susan Zolla-Pazner; Ian A Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2008-06-18

8.  Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.

Authors:  Xueling Wu; Anna Sambor; Martha C Nason; Zhi-Yong Yang; Lan Wu; Susan Zolla-Pazner; Gary J Nabel; John R Mascola
Journal:  Virology       Date:  2008-09-18       Impact factor: 3.616

9.  Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.

Authors:  Gwo-Yu Chuang; Yen-Ting Lai; Jeffrey C Boyington; Cheng Cheng; Hui Geng; Sandeep Narpala; Reda Rawi; Stephen D Schmidt; Yaroslav Tsybovsky; Raffaello Verardi; Kai Xu; Yongping Yang; Baoshan Zhang; Michael Chambers; Anita Changela; Angela R Corrigan; Rui Kong; Adam S Olia; Li Ou; Edward K Sarfo; Shuishu Wang; Winston Wu; Nicole A Doria-Rose; Adrian B McDermott; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

10.  Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Authors:  Miroslaw K Gorny; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Kathy Revesz; Bradley Witover; Sherri Burda; Mateusz Urbanski; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner; Arthur Nadas
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.